Hyderabad: Doctors at the LV Prasad Eye Institute in Hyderabad have discovered a new way to treat a rare but serious eye ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) today revealed it has approved Akantior (polihexanide) to ...

An evidence-based treatment protocol can improve outcomes in patients with Acanthamoeba keratitis, a study shows.

The European Commission has approved SIFI's Akantior as the first therapy anywhere in the world for acanthamoeba keratitis (AK), an ultra-rare parasitic infection that can lead to blindness.

AIM To review the clinical characteristics, diagnosis, and visual outcome in patients with non-contact lens related Acanthamoebakeratitis and compare the findings with reported series of contact lens ...

Acanthamoeba is a free-living protist pathogen, which is present in every place on Earth. 50 to 100 percent of the adult population has serum antibodies, specific for Acanthamoeba antigens.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved polihexanide (Akantior) to treat acanthamoeba keratitis. Acanthamoeba keratitis is an infection of the cornea, the clear ...

AIM To investigate the frequency, outcomes, and risk factors for acanthamoeba keratitis (AK) in England during the past 4 years. METHODS An ophthalmologist in 12 of the 14 regional health authorities ...

Acanthamoeba is an uncommon but serious cause of visual morbidity. Although Acanthamoeba spp are nearly ubiquitous in our environment, infection in humans is relatively rare. [1] Recently ...